The Health Transformation Alliance found diabetes patients whose blood sugar and weight didn't improve mostly kept refilling, as employers rethink 2027 coverage.
Recap by typeshit. Full story at Human Resources Director.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
Avi Roy points to trial data on drugs like Ozempic, including a 16-week study of 73 people where milkshake ratings barely changed despite reduced appetite.
Research presented at the anesthesiology meeting linked GLP-1 use with lower odds of heart attack and other heart problems. It shows an association, not proof of cause.
Fung argues that advice to just eat less misses the real driver, which he says is hunger. A short social post with no GLP-1 specifics.
Lembke, known for her work on addiction, discusses what FDA-approved GLP-1 weight loss drugs could do beyond weight. Details are on Stanford Medicine.
Loading…